Join the Non-Small Cell Lung Cancer group to help and get support from people like you.
Non-Small Cell Lung Cancer News (Page 5)
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
Surgical Treatment Provides Better Long-Term Survival for NSCLC
MONDAY, May 22, 2023 – Long-term survival favors surgical management over stereotactic body radiotherapy (SBRT) for treatment of early-stage, non-small cell lung cancer (NSCLC), according to a study...
Surgery Beats Targeted Radiation for Patients Battling Early Stage Lung Cancer
WEDNESDAY, May 10, 2023 – More patients are choosing radiation therapy over surgery to treat their early-stage lung cancer, but a new study argues they might be making a mistake. People who are good...
Cemiplimab + Chemotherapy Aids Quality of Life With Lung Cancer
WEDNESDAY, May 10, 2023 – Cemiplimab plus chemotherapy results in significant overall improvement in pain symptoms and delayed deterioration in cancer-related and lung cancer-specific symptoms and...
Dirty Air & Lung Cancer: Detroit Study Shows How Your Neighborhood Matters
TUESDAY, May 9, 2023 – Does where you live affect your risk for lung cancer? Just possibly, experts warn. Although cigarette smoking is the principal cause of most lung cancers, new research has...
Quitting Smoking Early Linked to Lower Mortality After NSCLC Diagnosis
FRIDAY, May 5, 2023 – For patients with non-small cell lung cancer (NSCLC), quitting smoking early is associated with lower mortality following diagnosis, according to a study published online May 5...
Patient-Centered Approach Recommended for Oligometastatic NSCLC
TUESDAY, May 2, 2023 – A patient-centered, multidisciplinary approach is strongly recommended for decision-making regarding treatment for oligometastatic non-small cell lung cancer (NSCLC),...
AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC
MONDAY, May 1, 2023 – For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant and adjuvant durvalumab offers benefits in terms of pathologic complete response and event-free...
FDA Approves Keytruda (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
Approval based on KEYNOTE-091 trial, which demonstrated a clinically meaningful improvement in disease-free survival with KEYTRUDA in these patients following surgical resection and platinum-based...
Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for Pemfexy in Combination with Pembrolizumab and Platinum Chemotherapy
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication...
FDA Approves Krazati (adagrasib) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO, Dec. 12, 2022 /PRNewswire/ – Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Imfinzi and Imjudo with Chemotherapy Approved in the US for Patients with Metastatic Non-Small Cell Lung Cancer
Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy 11 November 2022 – AstraZeneca’s I...
Libtayo (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced NSCLC...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
Enhertu Approved in the US as the First HER2-Directed Therapy for Patients with Previously Treated HER2-Mutant Metastatic Non-Small Cell Lung Cancer
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease 12 August 2022 – A...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Ask a question
To post your own question to this support group, sign in or create an account.